



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39 /00	A2	(11) International Publication Number: WO 00/03744 (43) International Publication Date: 27 January 2000 (27.01.00)
(21) International Application Number: PCT/US99/15942 (22) International Filing Date: 13 July 1999 (13.07.99) (30) Priority Data: 09/115,392 14 July 1998 (14.07.98) US (71) Applicant: AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US). (72) Inventors: LAPOSTA, Vincent, James; 24 Bromley Road, Pittsford, NY 14534 (US). ELDRIDGE, John, Hayward; 4 Beatrice Court, Fairport, NY 14450 (US). (74) Agents: BERG, Egon, E.; American Home Products Corpora- tion, Patent Law Dept. - 2B, One Campus Drive, Parsip- pany, NJ 07054 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ADJUVANT AND VACCINE COMPOSITIONS CONTAINING MONOPHOSPHORYL LIPID A		
(57) Abstract <p>The invention pertains to adjuvant and vaccine compositions of monophosphoryl lipid A, sugar and optionally an amine based surfactant, which when frozen and thawed or lyophilized and reconstituted reform a colloidal suspension having a light transmission of greater than or equal to 88 % as measured spectrophotometrically.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

5 **ADJUVANT AND VACCINE COMPOSITIONS CONTAINING**
 MONOPHOSPHORYL LIPID A

BACKGROUND OF THE INVENTION

10 1. Field of the Invention

 This invention relates to improved adjuvant and vaccine compositions, methods for preparing said improved adjuvant and vaccine compositions, and methods of using the improved compositions.

15 2. Description of the Prior Art

 Conventional vaccines have been used for many years to protect humans and animals from a wide variety of infectious diseases. Typically, these conventional vaccines contain one or more antigens which may include an
20 attenuated pathogen, killed pathogen, or an immunogenic component of a pathogen. In some vaccines, the antigen or antigens may be employed alone to elicit protective immune responses. In other vaccines, the antigen or antigens may be employed together with one or more adjuvants to enhance
25 the immunogenicity of an antigen. One such adjuvant known to the art is monophosphoryl lipid A, which is derived from the lipopolysaccharide of Salmonella minnesota R595. It is also known to the art that monophosphoryl lipid A is a lipidic material which spontaneously aggregates with itself
30 in an aqueous environment. Moreover, it is known that the degree of aggregation has an effect on the activity of monophosphoryl lipid A as an immunostimulant in that the aggregated monophosphoryl lipid A is less stimulatory.

 Monophosphoryl lipid A is typically obtained as
35 the triethylamine salt in the form of a lyophilized white powder. Being very hydrophobic, the lyophilized monophosphoryl lipid A does not readily form a clear solution when reconstituted with water but instead yields a turbid mixture with visible white particulates of
40 heterogeneous size that settle out and further aggregate

- 2 -

5 upon standing. To make an acceptable aqueous preparation of monophosphoryl lipid A, it is known to suspend the lyophilized monophosphoryl lipid A triethylamine salt at 1 to 2 mg/mL (w/v) in water containing 0.2% triethylamine, to heat the suspension at 65-70°C, and then to sonicate the
10 mixture. The resulting aqueous preparation, slightly opalescent or clear, is an aqueous colloidal suspension. The triethylamine aids in the solubilization of the monophosphoryl lipid A and may be substituted with similar amounts of triethanolamine.

15 When aqueous preparations of monophosphoryl lipid A prepared as described hereinabove are frozen and then thawed, however, the monophosphoryl lipid A aggregates resulting in a turbid mixture quite similar in appearance to the turbid mixture of monophosphoryl lipid A prior to
20 sonication. Similarly, when an aqueous preparation of monophosphoryl lipid A as described hereinabove is lyophilized and then rehydrated, the result is also a turbid mixture of aggregated monophosphoryl lipid A.

SUMMARY OF THE INVENTION

25 The present invention provides to the art a lyophilized composition containing monophosphoryl lipid A, which composition exhibits an enhanced reconstitution feature and which avoids the settling out and aggregation problems of the prior art. In particular, the present
30 invention provides a lyophilized composition comprising monophosphoryl lipid A, sugar and, optionally, an added amine based surfactant, and is capable of being reconstituted or rehydrated with an aqueous diluent to form, without further sonication, an aqueous colloidal
35 suspension of monophosphoryl lipid A having a light transmission of at least 88%, as measured spectrophotometrically. The lyophilized composition according to the present invention comprises up to about 5 wt% monophosphoryl lipid A, greater than about 70 wt% sugar
40 and from about 0 to about 30 wt% optionally added amine

- 3 -

5 based surfactant, said wt% based on the total of the
weights of monophosphoryl lipid A, sugar and, if present,
amine based surfactant. Preferably, the lyophilized
composition according to the present invention comprises up
to about 5 wt% monophosphoryl lipid A, from about 70 to
10 about 99.99 wt% sugar and from about 0 to about 28 wt%
optionally added amine based surfactant. More preferably,
the lyophilized composition according to the present
invention comprises up to about 4 wt% monophosphoryl lipid
A, from about 75 to about 99.99 wt% sugar and from about 0
15 to about 22 wt% optionally added amine based surfactant.
The lyophilized composition may further comprise an
immunologically effective amount of an antigen or antigens.
The lyophilized composition of the present invention may be
reconstituted or rehydrated with an aqueous diluent at
20 concentrations up to about 210 mg of lyophilized
composition per ml of aqueous diluent, preferably from
about 10 mg of lyophilized composition per ml of aqueous
diluent to about 210 mg of lyophilized composition per ml
of aqueous diluent, to form, without further sonication, an
25 aqueous colloidal suspension.

Another aspect of the present invention is a
method of preparing an aqueous colloidal suspension of
monophosphoryl lipid A in which the aqueous colloidal
suspension is frozen for storage and then thawed for use
30 without the problems of settling out and aggregation known
in the prior art. By this method, monophosphoryl lipid A
is mixed in an aqueous diluent and optionally with an amine
based surfactant and also optionally an antigen or
antigens. An aqueous colloidal suspension is formed by
35 sonicating, optionally with heating, or other known
methods, as described in greater detail hereinafter.
Sugar, in an amount from about 10 mg/ml to about 200 mg/ml,
is added to the mixture either before or after the
formation of an aqueous colloidal suspension. The sugar may
40 be in the form of a solid or in the form of an aqueous

- 4 -

5 solution. The resulting aqueous colloidal suspension may
then be frozen. Thawing the frozen aqueous colloidal
suspension affords without further sonication an aqueous
colloidal suspension containing monophosphoryl lipid A
having a light transmission of greater than or equal to
10 88%, as measured spectrophotometrically. An antigen or
antigens, as defined hereinafter, may be added to the
thawed aqueous colloidal suspension to form a vaccine
composition which may be administered to a vertebrate.
Alternatively, if the aqueous colloidal suspension contains
15 an antigen before freezing, the vaccine composition may be
thawed and administered to a vertebrate.

The aqueous colloidal suspensions of the present
invention are a special type of liquid suspension in which
the particles of suspended monophosphoryl lipid A are
20 present in very finely divided but not in dissolved form.
The aqueous colloidal suspensions containing monophosphoryl
lipid A, sugar and, optionally, an amine based surfactant
according to the present invention are true suspensions not
solutions, and do not have the property, unlike ordinary
25 suspensions of monophosphoryl lipid A, of settling out and
aggregation. The presence of the aqueous colloidal
suspensions of the present invention can be determined by
light transmission. Thus, an aqueous colloidal suspension
containing monophosphoryl lipid A, sugar and optionally an
30 amine based surfactant according to the present invention
is one which exhibits a light transmission of greater than
or equal to 88%, as measured spectrophotometrically.

The present invention solves the settling out
and aggregation problems of the prior art, by providing the
35 addition of sugar to an aqueous colloidal suspension of
monophosphoryl lipid A prior to freezing or lyophilization.
The sugar may be added either before or after formation of
the aqueous colloidal suspension but must be added before
freezing or lyophilization of the suspension. The addition
40 of sugar to an aqueous colloidal suspension of

- 5 -

5 monophosphoryl lipid A prior to freezing or lyophilization provides a composition which, after freezing can be thawed to afford an aqueous colloidal suspension without further sonication or, alternatively, after lyophilization, can be reconstituted with a suitable aqueous diluent and afford
10 without further sonication an aqueous colloidal suspension as described hereinabove. Suitable sugars include the monosaccharides, dextrose, mannose, galactose and fructose as well as the disaccharides sucrose, lactose, isomaltose, maltose and trehalose. Mixtures of sugars, for example
15 sucrose and dextrose, may also be employed. These sugars are all non toxic and pharmaceutically acceptable. Preferred are sucrose and dextrose. The sugar may be in the form of a solid or in the form of an aqueous solution. Suitable aqueous diluents include water or saline and can
20 also include an antigen or antigens and, may additionally contain preservatives or additional adjuvants, or other pharmaceutically acceptable additives, vehicles, or carriers. Suitable amine based surfactants include triethylamine (TEA) and triethanolamine (TEM).

25 A further aspect of the invention is a reconstituted or rehydrated aqueous colloidal suspension which, despite the elimination of a further sonication step, is obtained upon reconstitution of the lyophilized composition described hereinabove with an aqueous diluent.
30 As discussed hereinabove, before the present invention, a sonication step was necessary in order to obtain an aqueous colloidal suspension containing monophosphoryl lipid A. However, it has now been found that when an aqueous diluent is added to the lyophilized composition
35 described hereinabove, an aqueous colloidal suspension containing monophosphoryl lipid A is obtained without further sonication. The reconstituted aqueous colloidal suspension so obtained exhibits a light transmission of greater than or equal to 88%, when measured
40 spectrophotometrically. Surprisingly, the reconstituted

- 6 -

5 aqueous colloidal suspension so obtained is capable of
being frozen and, after thawing, again reforming an
aqueous colloidal suspension which exhibits a light
transmission of greater than or equal to 88%. The
reconstituted aqueous colloidal suspension of the present
10 invention comprises up to about 2.5 mg of monophosphoryl
lipid A per ml of aqueous diluent, from about 10 to 200 mg
of sugar per ml of aqueous diluent, and from about 0 to
about 6 mg of amine based surfactant per ml of aqueous
diluent. Preferably, the reconstituted aqueous colloidal
15 suspension of the present invention comprises up to about
2.0 mg of monophosphoryl lipid A per ml of aqueous
diluent, from about 20 to 150 mg of sugar per ml of
aqueous diluent and from about 0 to about 3 mg of amine
based surfactant per ml of diluent. The reconstituted
20 aqueous colloidal suspension may further comprise an
immunologically effective amount of an antigen or
antigens. Suitable sugars, amine based surfactants and
aqueous diluents are as described hereinabove.

A further aspect of the invention is a vaccine
25 composition comprising the lyophilized composition and the
reconstituted aqueous colloidal suspension described
hereinabove in combination with an immunologically
effective amount of an antigen or antigens. The effective
amount of an antigen or antigens may be optionally provided
30 in the aqueous diluent. In particular, the vaccine
composition further comprises an immunologically effective
amount of an antigen or antigens derived from or produced
by a bacterium, a virus, a parasite, a cancer cell or an
allergen. An effective amount of antigen is defined as
35 that amount of antigen that when administered to an animal
or a human evokes an immune response as measured by
production of specific antibodies or cell-mediated effector
mechanisms. Immunologically effective amounts of an
antigen or antigens are in general from about 1 μ g or less
40 to 5 mg. An effective amount of the monophosphoryl lipid A

- 7 -

5 adjuvant is the amount of monophosphoryl lipid A that when
added to a vaccine will enhance the magnitude or quality or
duration of the immune response to the antigen or antigens
in the vaccine. An effective amount of the adjuvant
monophosphoryl lipid A is in the range of about 1 μ g to
10 about 1 mg.

Suitable antigens for the vaccine compositions
of the present invention include any entity capable of
producing an antibody or cell-mediated immunological
response directed specifically against that entity in a
15 vertebrate exposed to the antigen. One or more antigens
may be employed. The antigen or antigens may be derived
from pathogenic micro-organisms including viruses,
bacteria, mycoplasmas, fungi, protozoa and other parasites.
Further, the antigen or antigens may be derived from
20 sources other than microorganisms, for example, cancer
cells or allergens. The antigen or antigens may be all or
part of a pathogenic microorganism, or all or part of a
protein, glycoprotein, glycolipid, polysaccharide or
lipopoly-saccharide which is associated with the organism,
25 or the antigen or antigens may be a polypeptide or other
entity which mimics all or part of such a protein,
glycoprotein, glycolipid, polysaccharide or
lipopolysaccharide.

Pathogenic microorganisms from which antigens
30 may be produced or derived for vaccine purposes are well
known in the field of infectious diseases, as listed in,
for example, Medical Microbiology, Second Edition, (1990)
J.C. Sherris (ed.), Elsevier Science Publishing Co., Inc.,
New York, and Zinsser Microbiology, 20th Edition (1992),
35 W.K. Joklik et al. (eds.), Appleton & Lange Publishing
Division of Prentice Hall, Englewood Cliffs, New Jersey.
Examples of organisms of interest for human vaccines
include *Chlamydia*, Nontypeable *Haemophilus influenzae*,
Helicobacter pylori, *Moraxella catarrhalis*, *Neisseria*
40 *gonorrhoeae*, *Neisseria meningitidis*, *Salmonella typhi*,

- 8 -

5 *Streptococcus pneumoniae*, Group A *Streptococcus*, Group B *Streptococcus*, Herpes Simplex Virus, Human Immunodeficiency Virus, Human Papilloma Virus, Influenza, Measles, Parainfluenza, Respiratory Syncytial Virus, Rotavirus, Norwalk Virus, and others.

10 The antigen or antigens may include glycoconjugates which comprise polysaccharide antigen or antigens, for example, bacterial capsular polysaccharide or fragment thereof, chemically linked to a protein carrier molecule in order to enhance immunogenicity. Methods for
15 preparing conjugates of bacterial capsular polysaccharide and protein carrier molecules are well known in the art and can be found, for example, in Dick and Burret, *Contrib Microbiol Immunol.* 10:48-114 (Cruse JM, Lewis RE Jr., eds; Basel Kruger (1989). Suitable conjugates, including
20 pneumococcal glycoconjugate, are described in greater detail in U.S. 4,673,574, U.S. 4,761,283, U.S. 4,902,506, U.S. 5,097,020 and U.S. 5,360,897 the contents of which are incorporated herein by reference.

 Also provided is a method of immunizing a
25 vertebrate through vaccination which comprises administering an effective amount of a vaccine composition according to the present invention to said vertebrate.

 Also provided is a method for the preparation of a lyophilized composition comprising:

30 a. suspending monophosphoryl lipid A in an amount up to about 5 mg/ml and, optionally, an amine based surfactant in an amount from 0 to about 6 mg/ml in an aqueous diluent;

35 b. forming an aqueous colloidal suspension having a light transmission of greater than or equal to 88%, as measured spectrophotometrically;

 c. adding sugar at about 10 to 200 mg/ml either before
40 or after forming the aqueous colloidal suspension;

- 9 -

- 5 d. lyophilizing the sugar containing aqueous colloidal suspension; and
- e. recovering a lyophilized composition.

Also provided is a method for preparing a lyophilized composition comprising:

- 10 a. heating lipopolysaccharide of gram negative bacteria Salmonella minnesota R595 in a mineral acid of moderate strength for a sufficient period of time to obtain a monophosphoryl derivative;
- b. dissolving the monophosphoryl derivative in an
15 organic solvent and drying;
- c. treating the monophosphoryl derivative with mild alkali to remove a base labile fatty acid chain at the
3 position to yield 3-deacylated monophosphoryl lipid A;
- d. purifying the 3-deacylated monophosphoryl lipid A
20 by liquid chromatography and recovering monophosphoryl lipid A;
- e. suspending monophosphoryl lipid A in an amount up to about 5 mg/ml and, optionally, an amine based surfactant in an amount from 0 to about 6 mg/ml in an
25 aqueous diluent;
- f. forming an aqueous colloidal suspension having a light transmission of greater than or equal to 88%, as measured spectrophotometrically;
- 30 g. adding sugar at about 10 to 200 mg/ml either before
or after forming the aqueous colloidal suspension;
- h. lyophilizing the sugar containing aqueous colloidal suspension; and
- 35 i. recovering a lyophilized composition.

- 10 -

- 5 Also provided is a method for the preparation of an aqueous colloidal suspension containing monophosphoryl lipid A capable of being frozen and thawed comprising:
- 10 a. suspending monophosphoryl lipid A in an amount up to about 5 mg/ml and, optionally, an amine based surfactant in an amount from 0 to about 6 mg/ml in an aqueous diluent;
- 15 b. forming an aqueous colloidal suspension having a light transmission of greater than or equal to 88%, as measured spectrophotometrically;
- c. adding sugar at about 10 to 200 mg/ml either before or after forming the aqueous colloidal suspension;
- 20 d. freezing the sugar containing aqueous colloidal suspension; and
- e. thawing and recovering the aqueous colloidal suspension.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

- 25 The preparation of monophosphoryl lipid A is described in U.S. Patent No. 4,912,094, the contents of which are incorporated herein by reference. Briefly, monophosphoryl lipid A is produced by refluxing lipopolysaccharide (or lipid A) obtained from heptoseless
- 30 mutants of gram negative bacteria, Salmonella minnesota R595, in mineral acid solutions of moderate strength (e.g., 0.1N HCl) for a period of approximately 30 minutes. Suitable mineral acids include hydrochloric, sulfuric and the like. This treatment results in the loss of the
- 35 phosphate moiety at position 1 of the reducing-end glucosamine. The core carbohydrate is removed from the 6' position of the non-reducing glucosamine during this treatment. The result is a monophosphoryl derivative of lipid A. The monophosphoryl derivative of lipid A is

- 11 -

5 dissolved in organic solvents and treated with very mild
alkali which removes the base-labile fatty acid chain at
the 3 position to yield 3-O-desacyl-4'-monophosphoryl lipid
A, indicating that position 3 of the reducing end
glucosamine is de-O-acylated. Chemically it is a mixture
10 of 3-deacylated monophosphoryl lipid A with 4, 5 or 6
acylated chains. Suitable organic solvents include methanol
(alcohols), dimethyl sulfoxide, dimethylformamide,
chloroform, dichloromethane and the like as well as
mixtures thereof. Combinations of water and one or more of
15 these organic solvents also can be employed. Suitable
alkaline bases can be chosen from among various hydroxides,
carbonates, phosphates and amines. Illustrative bases
include the inorganic bases such as sodium hydroxide,
potassium hydroxide, sodium carbonate, potassium carbonate,
20 sodium bicarbonate, potassium bicarbonate, and the like,
and organic bases such as alkyl amines and include, but are
not limited to, diethylamine, triethylamine and the like.
The 3-O-desacyl-4'-monophosphoryl lipid A is purified by
liquid chromatography and converted to the monobasic
25 triethylamine (triethylammonium) salt.

The term monophosphoryl lipid A as used herein
means 3-O-desacyl-4'-monophosphoryl lipid A as the
monobasic triethylamine (triethylammonium)salt.

To prepare the lyophilized composition of the
30 present invention, the monophosphoryl lipid A is added to
an aqueous diluent, preferably water, in amounts up to 5
mg of monophosphoryl lipid A per ml of aqueous diluent,
preferably up to 2.5 mg/ml and more preferably from about
0.5 to 2.5 mg/ml. Optionally, an added amine based
35 surfactant in an amount from about 0 to about 6 mg/ml,
preferably 0 to 3 mg/ml is employed.

An aqueous colloidal suspension having a light
transmission of greater than or equal to 88%, as measured
spectrophotometrically is formed by sonication, optionally
40 with heating, or other methods. Heating is optional but

- 12 -

5 preferred to facilitate the formation of the aqueous
colloidal suspension of monophosphoryl lipid A. Suitable
sonication equipment include, for example, a probe
sonicator (Vibracell VCX600; Sonica) attached to probes
whose sizes are appropriate for the volume being processed
10 or a bath sonicator such as the Model No. G112SP1T
obtained from Laboratory Supplies Co. Inc., (Hicksville,
NY). Other similar equipment used in the pharmaceutical
industry would also be appropriate for sonication of
monophosphoryl lipid A.

15 The aqueous colloidal suspension of monophosphoryl lipid A
may be formed by methods other than sonication, for
example, by shearing forces as would be generated in a
microfluidizer.

Sugar is also added either before or after
20 formation of the aqueous colloidal suspension, in amounts
from 10 to 200 mg sugar per ml of aqueous diluent,
preferably from about 20 to 150 mg/ml. The aqueous
colloidal suspension, containing monophosphoryl lipid A,
sugar and optionally an added amine based surfactant and
25 optionally an immunologically effective amount of an
antigen or antigens in the amounts recited hereinabove, is
lyophilized to afford the lyophilized composition according
to the present invention.

The aqueous colloidal suspension of
30 monophosphoryl lipid A, sugar and, optionally, an amine
based surfactant of an antigen or antigens is lyophilized
to afford the lyophilized composition of the present
invention. As is known to those skilled in the art,
lyophilization is a process of drying in which water is
35 sublimed from the product after it is frozen, by applying a
vacuum. Specifics of lyophilizing or freeze-drying are
described in Remington's Pharmaceutical Sciences. Chapter
84, page 1565, 18th Edition, A.R. Gennaro, Editor, 1990,
Mack Publishing Company.

- 13 -

5 Whether an aqueous colloidal suspension is
formed is determined by measuring the light transmission.
It has been found that compositions having a light
transmission of at least 88% exhibit the properties of
colloidal suspensions. Light transmission is measured
10 using a spectrophotometer in which is illuminated a liquid
sample in a glass, quartz or plastic cuvette with a light
path of 1 centimeter. The light may be in the visible or
invisible spectrum, but for measurements of light
transmission of this type a wavelength of 650 nm may
15 appropriately be used. The amount of light passing through
the sample (i.e. transmitted) is referenced to a blank
cuvette containing the solvent or diluent in which the
material is dissolved or suspended. Samples that do not
absorb or scatter the light will exhibit 100% light
20 transmission whereas those that absorb or scatter all the
light will have 0% light transmission.

While not wishing to be bound by theory, it is
believed that the advantageous results of the invention are
obtained because the addition of sugar either before or
25 after the formation of an aqueous colloidal suspension
containing monophosphoryl lipid A prevents the
monophosphoryl lipid A from aggregation either upon
freezing or thawing of the aqueous colloidal suspension or
upon lyophilizing the aqueous colloidal suspension and
30 reconstitution or rehydration with an aqueous diluent. By
including sugar in an aqueous colloidal suspension
containing monophosphoryl lipid A prior to lyophilization,
the lyophilized composition can be reconstituted with an
aqueous diluent such as water or saline without the problem
35 of reaggregation of the monophosphoryl lipid A. In
addition, freezing of the reconstituted colloidal
suspension or vaccine composition does not cause
aggregation to reoccur. Similarly, by including sugar in
an aqueous colloidal suspension containing monophosphoryl
40 lipid A prior to freezing, upon thawing a frozen aqueous

- 14 -

5 colloidal suspension is again obtained without the need for
further sonication. The ability of sugar to prevent
aggregation of the monophosphoryl lipid A is evident
regardless of whether the aqueous colloidal suspension
containing monophosphoryl lipid A is prepared in water
10 alone, or in water containing triethylamine or
triethanolamine.

Thus, the addition of sugar to monophosphoryl
lipid A containing aqueous compositions, either before or
after forming an aqueous colloidal suspension, provides
15 surprising and unexpected results when such aqueous
colloidal suspensions are either frozen and thawed or
lyophilized and reconstituted. Such results further permit
the advantageous preparation of vaccine compositions.

The following examples are provided to
20 illustrate the invention.

Example 1

Preparation of Turbid Mixture and Measurement of Light Transmission

Monophosphoryl lipid A (RIBI ImmunoChem.,
25 Hamilton, MT) is suspended in water at 1 mg/ml (w/v)
forming a turbid mixture with visible white particulates of
heterogeneous size. The turbid mixture is placed in a
Shimadzu UV-1601, UV-Visible Spectrophotometer and
illuminated with light of 650 nm wavelength. The turbid
30 mixture allows 3.3% of the incident light to pass (i.e.
%transmission = 3.3). An aqueous colloidal suspension is
not found.

Example 2

Preparation of Aqueous Colloidal Suspension and Measurement 35 of Light Transmission

Monophosphoryl lipid A, at 1 mg/ml (w/v) is
suspended in water containing 0.5% triethanolamine
(v/v) (5.62 mg/mL (w/v)) or 0.2% triethylamine (v/v) (1.46
mg/mL (w/v)). The samples are heated at 56-65°C for 10-15

- 15 -

5 minutes and sonicated using either a probe sonicator (Vibracell VCX600) set at 30% power using a tapered microtip or a bath sonicator (Model No. G112SP1T, Laboratory Supplies Co. Inc., Hicksville, NY.) used at full power for 2 to 3 minutes. A clear suspension is obtained and placed in a Shimadzu UV-1601, UV-Visible Spectrophotometer and illuminated with light of 650 nm wavelength. The % light transmission is measured at $\geq 88\%$, indicating the formation of an aqueous colloidal suspension.

15

Example 3

Preparation of Aqueous Colloidal Suspension of Monophosphoryl lipid A and Lyophilization

Aqueous colloidal suspensions of monophosphoryl lipid A are formed by suspending monophosphoryl lipid A, at 1, 2 or 5 mg/mL (w/v) in water or water containing either 0.5% triethanolamine v/v (5.6 mg/mL w/v), or 0.2% triethylamine v/v (1.46 mg/mL w/v). Each Monophosphoryl lipid A suspension is heated for 10-15 minutes at 56°C to 65°C and then sonicated for a total of 2-3 minutes to obtain a clear suspension with no visual evidence of particulates. The samples (1 to 1.5 ml) are sonicated using either a probe sonicator (Vibracell VCX600) set at 30% power using a tapered microtip or a bath sonicator (Model No. G112SP1T, Laboratory Supplies Co. Inc., Hicksville, NY.) used at full power. Aliquots of the monophosphoryl lipid A aqueous colloidal suspensions above are diluted with an equal amount of water, or sucrose or dextrose solutions of varying concentrations. The resulting aqueous colloidal suspensions include monophosphoryl lipid A at 0.5, 1.0 or 2.5 mg/mL (w/v) and sucrose at final concentrations of 10, 50, 100 or 200 mg/ml (w/v) or dextrose at 10, 50, 100 or 170 mg/ml (w/v) as expressed in Table 1. The preparations contained either triethanolamine (TEM) at 2.81 or 5.62 mg/mL or triethylamine (TEA) at 0.73

-16-

mg/mL or no amine based surfactant. The samples are placed in a Shimadzu UV-1601, UV-Visible Spectrophotometer and illuminated with light of 650 nm wavelength. The % light transmission, as set forth in Table 1, ranges from 90.0 to 99.9%, indicating the formation of an aqueous colloidal suspension.

TABLE 1. COMPOSITION OF MONOPHOSPHORYL LIPID A FORMULATIONS

						% light transmission
Sample	MPL mg/mL	sugar added	sugar mg/mL	Amine added	Added Amine mg/mL	
1	0.5	sucrose	10	TEM	2.81	97.2
2	0.5	dextrose	10	TEM	2.81	97.1
3	0.5	sucrose	10	TEM	2.81	97.2
4	0.5	dextrose	10	TEM	2.81	97.3
5	0.5	sucrose	10	TEA	0.73	98.9
6	0.5	sucrose	10	TEA	0.73	98.4
7	0.5	sucrose	50	TEM	5.62	95.9
8	0.5	sucrose	50	TEM	5.62	96.0
9	0.5	sucrose	50	TEM	2.81	97.5
10	0.5	dextrose	50	TEM	2.81	97.4
11	0.5	sucrose	50	TEM	2.81	97.5
12	0.5	dextrose	50	TEM	2.81	97.4
13	0.5	sucrose	50	TEA	0.73	98.8
14	0.5	sucrose	50	TEA	0.73	99

-17-

TABLE 1. (CONTINUED) COMPOSITION OF MONOPHOSPHORYL LIPID
A FORMULATIONS

						% light transmission
Sample	MPL mg/mL	sugar added	sugar mg/mL	Amine added	Added Amine mg/mL	
15	0.5	sucrose	50	-	0	96.1
16	0.5	sucrose	50	-	0	96.0
17	0.5	sucrose	100	TEM	2.81	97.6
18	0.5	dextrose	100	TEM	2.81	97.6
19	0.5	sucrose	100	TEM	2.81	97.4
20	0.5	dextrose	100	TEM	2.81	97.6
21	0.5	dextrose	170	TEM	2.81	98.2
22	0.5	dextrose	170	TEM	2.81	98.1
23	0.5	dextrose	200	TEM	2.81	98.4
24	0.5	sucrose	200	TEM	2.81	98.4
25	0.5	sucrose	200	TEM	2.81	97.7
26	0.5	sucrose	200	TEM	2.81	97.8
27	0.5	sucrose	200	TEA	0.73	99.4
28	0.5	sucrose	200	TEA	0.73	99.4
29	0.5	sucrose	200	TEA	0.73	98.9
30	0.5	sucrose	200	TEA	0.73	98.9
31	1.0	sucrose	200	TEA	0.73	97.7
32	1.0	sucrose	200	TEA	0.73	97.6
33	1.0	sucrose	200	TEM	2.81	95.7
34	1.0	sucrose	200	TEM	2.81	95.6
35	2.5	sucrose	200	TEM	2.81	90.1
36	2.5	sucrose	200	TEM	2.81	90.0
37	2.5	sucrose	200	TEA	0.73	95.4
38	2.5	sucrose	200	TEA	0.73	95.3

- 18 -

5

Lyophilization of Monophosphoryl Lipid A Adjuvant
Compositions

The aqueous colloidal suspensions set forth in Table 1 are lyophilized by first freezing the samples in glass vials or polypropylene culture tubes on dry ice pellets for at least 30 minutes. They are then transferred to large freeze drying vessels (Labconco) and connected to a Virtus Freeze Dryer. The samples are lyophilized for 18 hours at a vacuum of 250 millitons and the condenser temperature of -50° C. The composition of the lyophilized adjuvant compositions are shown in Table 2.

Reconstitution of Lyophilized Adjuvant Compositions

The lyophilized samples as set forth in Table 2 are reconstituted with either water or normal saline (0.9% NaCl w/v), the volume of which was equal to the volume of the aqueous colloidal suspension prior to lyophilization. Data showing the % light transmission of the samples after reconstitution with aqueous diluent are presented in Table 2. As shown in Table 2, the lyophilized compositions, containing sucrose or dextrose ranging from greater than 75% up to 99.4% of the composition by weight, gave rise to aqueous colloidal suspensions when rehydrated with water or saline. For samples 1-38 set forth in Table 2, the % transmission after rehydration ranged from 88.0% to 98.4% indicating the formation of an aqueous colloidal suspension. Samples 15 and 16, which contained 99% sugar by weight after lyophilization, were prepared without the addition of amines (triethylamine or triethanolamine) at the time of sonication. When rehydrated with either water or normal saline, %transmission values are measured at 96.1 and 93.6, respectively, indicating the formation of an aqueous colloidal suspension. These data show that when an aqueous colloidal suspension of Monophosphoryl lipid A prepared by sonication is lyophilized with an effective

- 19 -

- 5 amount of sugar such as sucrose or dextrose it can be rehydrated with water or normal saline to regain an aqueous colloidal suspension.

-20-

Table 2. Light transmission properties of lyophilized Monophosphoryl Lipid A compositions after rehydration with water or normal saline.

Sample	Composition Wt.% after lyophilization			Diluent for rehydration	% light transmission after rehydration
	% MPL	% sugar	% Added Amine		
1	3.8	75.1	21.1	water	95.8
2	3.8	75.1	21.1	water	96.1
3	3.8	75.1	21.1	saline	95.5
4	3.8	75.1	21.1	saline	95.4
5	4.5	89.0	6.5	water	96.5
6	4.5	89.0	6.5	saline	94.8
7	0.9	89.1	10	water	95.7
8	0.9	89.1	10	saline	95.7
9	0.9	93.8	5.3	water	96.0
10	0.9	93.8	5.3	water	96.6
11	0.9	93.8	5.3	saline	95.7
12	0.9	93.8	5.3	saline	96.3
13	1.0	97.6	1.4	water	98.4
14	1.0	97.6	1.4	saline	96.3
15	1.0	99.0	0	water	96.1
16	1.0	99.0	0	saline	93.6
17	0.5	96.8	2.7	water	96.4
18	0.5	96.8	2.7	water	97.1
19	0.5	96.8	2.7	saline	95.8
20	0.5	96.8	2.7	saline	96.8
21	0.3	98.1	1.6	water	97.4
22	0.3	98.1	1.6	saline	96.6
23	0.2	98.4	1.4	water	97.7
24	0.2	98.4	1.4	saline	96.8
25	0.2	98.4	1.4	water	97.2
26	0.2	98.4	1.4	saline	96.9
27	0.2	99.4	0.4	water	98.4
28	0.2	99.4	0.4	saline	96.7

- 21 -

- 5 Table 2. (Continued) Light transmission properties of lyophilized Monophosphoryl Lipid A compositions after rehydration with water or normal saline

	Wt.% of Composition after lyophilization				% light transmission after rehydration
Sample	% MPL	% sugar	% Added Amine	Diluent for rehydration	
29	0.2	99.4	0.4	water	95.5
30	0.2	99.4	0.4	saline	96.7
31	0.5	99.1	0.4	water	97.1
32	0.5	99.1	0.4	saline	96.1
33	0.5	98.1	1.4	water	95.0
34	0.5	98.1	1.4	saline	94.6
35	1.2	97.4	1.4	water	89.8
36	1.2	97.4	1.4	saline	88.0
37	1.2	98.4	0.4	water	94.8
38	1.2	98.4	0.4	saline	90.8

Example 4

- 10 Using the procedures set forth in Example 3, formulations containing monophosphoryl lipid A, sugar and amine in the amounts set forth in Table 3 are prepared. The light transmission of these formulations is measured and as set forth in Table 3, % light transmission ranges
- 15 from 95.4 to 98.8% indicating the formation of an aqueous colloidal suspension.

-22-

TABLE 3. COMPOSITION OF MONOPHOSPHORYL LIPID A FORMULATIONS

Sample						% Light Transmission
	MPL mg/mL	sugar added	sugar mg/mL	Amine added	Added Amine mg/mL	
39	0.5	-	0	TEM	5.62	95.8
40	0.5	-	0	TEM	2.81	97.1
41	0.5	-	0	TEA	0.73	98.8
42	0.5	-	0	-	0	95.8
43	0.5	-	0	-	0	95.9
44	0.5	sucrose	0.5	TEM	5.62	95.5
45	0.5	sucrose	1	TEM	5.62	95.4
46	0.5	sucrose	5	TEM	5.62	95.5
47	0.5	sucrose	10	TEM	5.62	95.6

Using the procedures set forth in Example 3, the formulations of Table 3 are lyophilized and reconstituted with water or saline as set forth in Table 4.

Table 4. Light transmission properties of lyophilized Monophosphoryl Lipid A formulations after rehydration with water or normal saline.

Sample	Wt. % of Composition after lyophilization			Diluent for rehydration	% light transmission after rehydration
	% MPL	% sugar	% Added Amine		
39	8.2	0.0	91.8	water	58.6
40	15.1	0.0	84.9	water	58.2
41	40.7	0.0	59.3	water	22
42	100.0	0.0	0	water	32.8
43	100.0	0.0	0	saline	30.2
44	7.6	7.6	84.9	water	63.1
45	7.0	14.0	78.9	water	64.7
46	4.5	45.0	50.5	water	50.6
47	3.1	62.0	34.9	water	83.5

When samples lyophilized without sugars (samples 39-43) are rehydrated with water or saline the resultant preparation is turbid with suspended particulates. These samples exhibit a % transmission ranging from 22.0 to 58.6.

- 23 -

- 5 Similar results are obtained when samples 44-47 containing 7.6% to 62.0% sugar are rehydrated with water indicating that an aqueous colloidal suspension is not formed.

Example 5

10 Freezing and Thawing of Monophosphoryl Lipid A Sonicated in Aqueous Triethylamine in the Presence of Sucrose

- Monophosphoryl lipid A is sonicated in water containing 0.2% triethylamine (v/v) and then admixed with an equal volume of water or with water containing added sucrose to yield a clear suspension containing
- 15 monophosphoryl lipid A at 0.5 mg/mL (w/v) without sucrose or containing 100 mg/mL sucrose w/v and triethylamine at a final concentration of 0.1% v/v (0.73 mg/mL w/v). The samples (48 and 49) are placed in a Shimadzu UV-1601, UV-Visible Spectrophotometer and illuminated with light of 650
- 20 nm and each allowed 98.8% of the light to pass thus indicating the formation of an aqueous colloidal suspension. The colloidal suspensions are frozen and then thawed. Upon thawing, the monophosphoryl lipid A preparation without sucrose (sample 48) is turbid with
- 25 particulates and has a % light transmission of 60.3% as measured in a Shimadzu UV-1601, UV-Visible Spectrophotometer and illuminated with light of 650 nm wavelength indicating that an aqueous colloidal suspension is not formed. The monophosphoryl lipid A containing sucrose
- 30 (sample 49) remains clear after freezing and thawing and has a % light transmission of 97.8% as measured in a Shimadzu UV-1601, UV-Visible Spectrophotometer and illuminated with light of 650 nm wavelength indicating the formation of an aqueous colloidal suspension. These data
- 35 are displayed in Table 5.

TABLE 5. Light transmission properties before and after freezing and thawing of Monophosphoryl Lipid A sonicated with triethylamine and diluted with or without sucrose

Sample	Composition of MPL preparations			% light transmission		Appearance after thawing
	MPL (mg/mL)	Sucrose (mg/mL)	Added TEA (mg/mL)	Before freezing	After thawing	
48	0.5	0	0.73	98.8	60.3	Turbid
49	0.5	100	0.73	98.8	97.8	Clear

Example 6 - Preparation of Vaccine Compositions:

a. Preparation of aqueous colloidal suspensions of monophosphoryl lipid A

Using the procedures set forth in Example 3 above, a mixture of monophosphoryl lipid A in water of about 0.5 mg/ml and an amine-based surfactant triethanolamine at about 2.8 mg/ml is heated and sonicated to give an aqueous colloidal suspension. Either before or after sonication, but prior to freezing or lyophilizing, sucrose is added at a final concentration between about 10 to 200 mg/ml. The aqueous colloidal suspension so obtained may be either frozen and thawed for use in a vaccine composition or lyophilized and reconstituted with an aqueous diluent for use in a vaccine composition.

b. Preparation of an aqueous vaccine composition from frozen monophosphoryl lipid A composition

The aqueous colloidal suspension of monophosphoryl lipid A, sucrose and triethanolamine prepared as in (a) above is frozen. It is then thawed and combined with an aqueous diluent containing an antigen, for example, a pneumococcal glycoconjugate prepared according to U.S. Patent

- 25 -

5 5,360,897, to obtain a vaccine composition containing up to
about 400 micrograms monophosphoryl lipid A per ml and up
to about 200 micrograms pneumococcal glycoconjugate per ml.
To obtain a vaccine composition containing 400 micrograms
of monophosphoryl lipid A and 200 micrograms of
10 pneumococcal glycoconjugate, for example, 0.8 ml of the
thawed colloidal suspension may be combined with 200
micrograms of pneumococcal glycoconjugate in 0.2 ml of
water. This vaccine composition may then be administered
to a vertebrate, preferably to a human, using about 0.1 to
15 1.0 ml per dose.

c. Preparation of an aqueous vaccine composition from
lyophilized monophosphoryl lipid A composition

20 The aqueous colloidal suspension of monophosphoryl lipid A,
sucrose and triethanolamine prepared in (a) above is
lyophilized. It is then reconstituted with an aqueous
diluent containing an antigen, for example, a pneumococcal
glyco-conjugate prepared according to U.S. Patent
25 5,360,897, to obtain a vaccine composition containing up to
about 400 micrograms monophosphoryl lipid A per ml and up
to about 200 micrograms pneumococcal glycoconjugate per ml.
This vaccine composition may then be administered to a
vertebrate, preferably to a human, using about 0.1 to 1.0
30 ml per dose.

d. Preparation of a frozen aqueous vaccine composition

To the aqueous colloidal suspension of monophosphoryl lipid
35 A, sucrose and triethanolamine prepared in (a) above is
added an antigen, for example, a pneumococcal
glycoconjugate prepared according to U.S. Patent 5,360,897
to obtain a vaccine composition. The vaccine composition
is then frozen. The concentrations of monophosphoryl lipid
40 A and pneumococcal glycoconjugate are adjusted by addition

- 26 -

5 of a aqueous diluent, to up to about 400 micrograms per ml
and up to about 200 micrograms per ml, respectively, either
before freezing or after freezing and thawing, provided
that the sucrose is kept at a concentration of about 10 to
200 mg/ml before freezing. The frozen and thawed vaccine
10 composition may then be administered to a vertebrate,
preferably to a human, using about 0.1 to 1.0 ml per dose.

e. Preparation of a lyophilized vaccine composition

15 To the aqueous colloidal suspension of monophosphoryl lipid
A, sucrose and triethanolamine prepared in (a) above is
added, for example, a pneumococcal glycoconjugate prepared
according to U.S. Patent 5,360,897 to obtain a vaccine
composition. The antigen may be added either before or
20 after the heating and sonicating steps. The amount of
pneumococcal glycoconjugate added is calculated such that,
upon subsequent reconstitution of the lyophilized vaccine
composition, the aqueous mixture will contain up to about
400 micrograms of monophosphoryl lipid A per ml and up to
25 about 200 micrograms pneumococcal glycoconjugate per ml.
The vaccine composition is then lyophilized. Following
lyophilization, the composition is reconstituted with an
aqueous diluent. This reconstituted aqueous vaccine
composition may then be administered to a vertebrate,
30 preferably to a human, using about 0.1 to 1.0 ml per dose.

- 27 -

5

What is claimed:

- 10 1. A lyophilized composition comprising 3-O-desacyl-4'-monophosphoryl lipid A in an amount up to about 5% by weight, greater than about 70% by weight of sugar and about 0 to about 30% by weight of an added amine based surfactant.
- 15 2. The lyophilized composition according to Claim 1 comprising 3-O-desacyl-4'-monophosphoryl lipid A in an amount up to about 4% by weight, sugar from about 75 to about 99.99% by weight and amine based surfactant from about 0 to about 22% by weight.
- 20 3. The lyophilized composition according to Claim 1 wherein the sugar comprises dextrose, mannose, galactose, fructose, sucrose, lactose, isomaltose, maltose or trehalose.
- 25 4. The lyophilized composition according to Claim 1 wherein the sugar is sucrose or dextrose.
- 30 5. The lyophilized composition according to Claim 1 wherein the amine based surfactant is triethylamine or triethanolamine.
- 35 6. The lyophilized composition according to Claim 1 further comprising an immunologically effective amount of an antigen or antigens.
- 40 7. A vaccine composition comprising an amount of the lyophilized composition of Claim 1 sufficient to provide an effective amount of 3-O-desacyl-4'-monophosphoryl lipid A and an immunologically effective amount of an antigen or antigens.

- 28 -

- 5
8. The vaccine composition according to Claim 7 wherein the antigen or antigens are derived from or produced by a bacterium, a virus, a parasite, a cancer cell or an allergen.
- 10
9. The vaccine composition according to Claim 7 wherein the antigen is a *Chlamydia*, Nontypeable *Haemophilus influenzae*, *Helicobacter pylori*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*,
- 15 *Salmonella typhi*, *Streptococcus pneumoniae*, Group A *Streptococci*, Group B *Streptococcus*, Herpes Simplex Virus, Human Immunodeficiency Virus, Human Papilloma Virus, Influenza, Measles, Parainfluenza, Respiratory Syncytial Virus, Rotavirus, or Norwalk Virus antigen.
- 20
10. The vaccine composition according to Claim 7 wherein the immunologically effective amount of an antigen or antigens is about 1 μg to about 5 mg.
- 25
11. The vaccine composition according to Claim 7 wherein an effective amount of 3-O-desacyl-4'-monophosphoryl lipid A is about 1 μg to about 1 mg.
- 30
12. The vaccine composition according to Claim 7 wherein the antigen is a conjugate comprising capsular polysaccharide of *Streptococcus pneumoniae* covalently attached to protein.
- 35
13. An aqueous composition comprising the lyophilized composition of Claim 1 reconstituted with an aqueous diluent at an amount up to about 210 mg of the lyophilized composition per ml of aqueous diluent, said aqueous composition in the form of an aqueous colloidal suspension having a light transmission of

- 29 -

- 5 greater than or equal to 88% as measured
spectrophotometrically.
14. The aqueous composition of Claim 13 comprising per ml
of aqueous diluent up to about 2.5 mg of 3-O-desacyl-
10 4'-monophosphoryl lipid A from about 10 to about 200 mg
of sugar and about 0 to about 6 mg of an added amine
based surfactant.
15. The aqueous composition according to Claim 13
15 comprising per ml of aqueous diluent from about .5 to
about 2.5 mg of 3-O-desacyl-4'-monophosphoryl lipid A
from about 20 to about 150 mg sugar, and from about 0
to about 3 mg of added amine based surfactant.
- 20 16. The aqueous composition according to Claim 13 wherein
said sugar is sucrose or dextrose.
17. The aqueous composition of Claim 13 wherein said
aqueous diluent comprises water or saline.
25
18. The aqueous composition of Claim 13 wherein said
aqueous diluent further comprises an antigen or
antigens, an aluminum phosphate or other adjuvant, or a
pharmaceutically acceptable carrier.
30
19. The aqueous composition of Claim 13 wherein said amine
based surfactant is triethylamine or triethanolamine.
20. A vaccine composition comprising an amount of the
35 aqueous composition of Claim 13 sufficient to provide
an effective amount of 3-O-desacyl-4'-monophosphoryl
lipid A and an immunologically effective amount of an
antigen or antigens.

- 30 -

- 5 21. The vaccine composition according to Claim 20 wherein the antigen or antigens are derived from or produced by a bacterium, a virus, a parasite, a cancer cell or an allergen.
- 10 22. The vaccine composition according to Claim 20 wherein the antigen is a conjugate comprising capsular polysaccharide of *Streptococcus pneumoniae* covalently attached to protein.
- 15 23. The vaccine composition according to Claim 20 wherein the antigen is a *Chlamydia*, Nontypeable *Haemophilus influenzae*, *Helicobacter pylori*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Salmonella typhi*, *Streptococcus*
- 20 *pneumoniae*, Group A *Streptococci*, Group B *Streptococcus*, Herpes Simplex Virus, Human Immunodeficiency Virus, Human Papilloma Virus, Influenza, Measles, Parainfluenza, Respiratory Syncytial Virus, Rotavirus, or Norwalk Virus antigen.
- 25 24. The vaccine composition according to Claim 20 wherein the effective amount of the antigen is about 1 ug to about 5 mg.
- 30 25. The vaccine composition according to Claim 20 wherein the effective amount of 3-O-desacyl-4'-monophosphoryl lipid A is about 1 ug to about 1 mg.
- 35 26. A method of immunizing a vertebrate through vaccination which method comprises administering a vaccine composition according to claim 20 to a vertebrate.
27. A method for the preparation of a lyophilized composition comprising:

- 31 -

- 5 a. suspending 3-O-desacyl-4'-monophosphoryl lipid A in an amount up to about 5 mg/ml and an amine based surfactant in an amount from 0 to about 6 mg/ml in an aqueous diluent;
- 10 b. forming an aqueous colloidal suspension having a light transmission of greater than or equal to 88%, as measured spectrophotometrically;
- 15 c. adding sugar at about 10 to 200 mg/ml either before or after forming the aqueous colloidal suspension;
- d. lyophilizing the sugar containing aqueous colloidal suspension; and
- e. recovering a lyophilized composition.
28. The lyophilized composition prepared according to the method of claim 27.
- 20 29. A method for preparing a lyophilized composition comprising:
- a. heating lipopolysaccharide of gram negative bacteria Salmonella minnesota R595 in a mineral acid of moderate strength for a sufficient period of time to obtain a monophosphoryl derivative;
- 25 b. dissolving the monophosphoryl derivative in an organic solvent and drying;
- c. treating the monophosphoryl derivative with mild alkali to remove a base labile fatty acid chain at the 3 position to yield 3-O-desacyl-4'-monophosphoryl lipid A;
- 30 d. purifying the 3-O-desacyl-4'-monophosphoryl lipid A by liquid chromatography and recovering 3-O-desacyl-4'-monophosphoryl lipid A;
- 35 e. suspending 3-O-desacyl-4'-monophosphoryl lipid A in an amount up to about 5 mg/ml and, an amine based

- 32 -

- 5 surfactant in an amount from 0 to about 6 mg/ml in an aqueous diluent;
- f. forming an aqueous colloidal suspension having a light transmission of greater than or equal to 88%, as
10 measured spectrophotometrically;
- g. adding sugar at about 10 to 200 mg/ml either before or after forming the aqueous colloidal suspension;
- h. lyophilizing the sugar containing aqueous colloidal
15 suspension; and
- i. recovering a lyophilized composition.
30. A method for the preparation of an aqueous colloidal suspension containing 3-O-desacyl-4'-
20 monophosphoryl lipid A capable of being frozen and thawed comprising:
- a. suspending 3-O-desacyl-4'-monophosphoryl lipid A in an amount up to about 5 mg/ml and, an amine based
25 surfactant in an amount from 0 to about 6 mg/ml in an aqueous diluent;
- b. forming an aqueous colloidal suspension having a light transmission of greater than or equal to 88%, as
30 measured spectrophotometrically;
- c. adding sugar at about 10 to 200 mg/ml either before or after forming the aqueous colloidal suspension;
- d. freezing the sugar containing aqueous colloidal
35 suspension; and
- e. thawing and recovering the aqueous colloidal suspension.

- 33 -

- 5 31. The method of claim 30 wherein said thawed aqueous colloidal suspension is combined with an aqueous diluent further containing an antigen or antigens, aluminum phosphate adjuvant or a pharmaceutically acceptable preservative, carrier or vehicle.
- 10 32. A method for the preparation of an aqueous colloidal suspension containing 3-O-desacyl-4'-monophosphoryl lipid A capable of being lyophilized and resuspended comprising:
- 15 a. suspending 3-O-desacyl-4'-monophosphoryl lipid A in an amount up to about 5 mg/ml and, an amine based surfactant in an amount from 0 to about 6 mg/ml in an aqueous diluent;
- 20 b. forming an aqueous colloidal suspension having a light transmission of greater than or equal to 88%, as measured spectrophotometrically;
- c. adding sugar at about 10 to 200 mg/ml either before or after forming the aqueous colloidal suspension;
- 25 d. lyophilizing the sugar containing aqueous colloidal suspension; and
- e. resuspending and reforming an aqueous colloidal suspension.
- 30 33. The method of claim 32 wherein said lyophilized aqueous colloidal suspension is combined with an aqueous diluent further containing an antigen or antigens, aluminum phosphate adjuvant or a pharmaceutically acceptable preservative, carrier or vehicle.